Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipelineAppointment further expands Oculis' executive leadership team and bolsters U.S. presence ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chie

Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah's joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations for global marketing applications including its first NDA submission to the U.S. FDA ZUG, Switzerland and BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a

Completed enrollment in Phase 2b RELIEF trial of Licaminlimab (OCS-02), anti-TNF (tumor necrosis factor) alpha eye drops in Dry Eye Disease (DED); topline results expected in Q2 2024Second Phase 3 trial (DIAMOND-2) of OCS-01 eye drops in Diabetic Macular Edema (DME) initiated as planned, in addition to the ongoing DIAMOND-1 Phase 3 trial initiated in late 2023World-renowned retina specialists, Professor Ramin Tadayoni, M.D., Ph.D. appointed as Chief Scientific Officer and Arshad M. Khanani, M.D., M.A., FASRS appointed as Chair of Oculis' Retina Scientific Advisory Board (SAB)Seasoned HR executive, Virginia R. Dean, appointed as Chief Human Resources Officer in Boston ZUG, Switzerland, a

Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME)Enrolled first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for treatment of cystoid macular edema (CME)Cash and investments of $116.5 million adequately funded to deliver on key business and clinical milestones ZUG, Switzerland and BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve e

Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01's recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery propels Oculis into pre-commercial phase in anticipation of the Company's first US commercial launchIf approved, OCS-01 has the potential to become the first topical preservative-free eye

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective structural measures of retinal thickness and visual improvementIND clearance from FDA enables initiation of clinical development in the U.S as part of a global development program Planning next steps for OCS-05 as a potential first-in-class neuroprotective therapy for acute

ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be present at the Stifel 2024 Healthcare Conference being held on November 18-19, 2024 at the Lotte New York Palace Hotel in New York, NY. Sylvia Cheung, Chief Financial Officer of Oculis, will participate in a fireside chat on November 18, 2024 at 3:35 pm ET. A live webcast of the fireside chat will be available here. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Stifel representative to

Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into 2H 2026 ZUG, Switzerland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to

Phase 3 DIAMOND-1 and DIAMOND-2 trials enrollment of OCS-01 in diabetic macular edema (DME) accelerated with great momentumDIAMOND program committees expanded with globally renowned retina experts If approved, OCS-01 has the potential to transform the treatment paradigm as the first topical eye drop to treat DME ZUG, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces the acceleration of patient enrollment for both Phase 3 DIAMOND trials of OCS-01 eye drops in DME and expansion of the DIAMOND program committees with globally renowned retina exper

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that an update on the DIAMOND Phase 3 program with OCS-01, an OPTIREACH® formulation of high concentration dexamethasone eye drop, for diabetic macular edema (DME) will be presented by David Eichenbaum, M.D. at Innovate Retina. In addition, Riad Sherif, M.D., Oculis' Chief Executive Officer, will be presenting at Eyecelerator 2024, ahead of the American Academy of Ophthalmology Annual Meeting where Oculis will be exhibiting (booth 5452). Both presentations from Dr. Eichenbaum and Dr. Sherif

Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

ZUG, Switzerland, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, in collaboration with EURETINA, today announced the winner of the Inaugural Ramin Tadayoni Award. The Ramin Tadayoni Award was established in memory of Oculis' Chief Scientific Officer and a world-renowned retina specialist in order to pay a lasting tribute to Professor Tadayoni's legacy, who passed away unexpectedly earlier this year. The first recipient of the award is Andrea Govetto, M.D., Ph.D. who is developing a computational model of fluid flow and retinal tissue deformation in macular edema.

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the following upcoming investor conferences: Wells Fargo Healthcare Conference 2024Event dates: September 4-6, 2024Location: Encore Boston Harbor, Boston, MA H.C. Wainwright 26th Annual Global Investment ConferenceEvent dates: September 9-11, 2024Company Presentation by Riad Sherif, MD, Chief Executive Officer on September 11 at 9:30 am ET Location: Lotte New York Palace Hotel, NY, NY Baird Global Healthcare Conference 2024Event

Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED)Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for topline readout in Q4 2024Pre-NDA meeting with U.S. Food and Drug Administration (FDA) completed in August for once daily OCS-01 for the treatment of post-operative inflammation and pain following ocular surgery; Providing a clear path forward for NDA submission in Q1 2025, while randomization in Phase 3 DIAMOND-1 and DIAMOND-2 trials in diabetic macular edema (DME) is on trackCash, cash equivalents and short-term investments of $131.2 million as

Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

H.C. Wainwright initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $28.00

Robert W. Baird initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $58.00

Pareto initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $23.00

Wedbush initiated coverage of Oculis Holding AG with a rating of Outperform and set a new price target of $27.00

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

EFFECT - Oculis Holding AG (0001953530) (Filer)

424B3 - Oculis Holding AG (0001953530) (Filer)

F-3 - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)

6-K - Oculis Holding AG (0001953530) (Filer)